Skip to main content
. 2021 Apr 16;12:244. doi: 10.1186/s13287-021-02246-4

Fig. 5.

Fig. 5

Sixth-month graft biopsies. Representative sections of the livers stained with CK19, including cases of no biliary complications and cases of ITBL during MSCs or rituximab treatment (× 200 magnification). a No biliary complications occurred in the MSC group, and the bile ducts stained with CK19 were normal. b CK19 staining of patients with or without biliary complications in the rituximab group. Abnormal changes included dilation and atresia of the bile ducts with ITBL